Table 3.
Overview of primary and secondary analyses of post-treatment BP impact on various outcomes
| Clinical outcome | BP level | Unadjusted analyses |
Adjusted analyses* |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Studies | SMD (95% CI) | P | Heterogeneity | Studies | OR (95% CI) | P | Heterogeneity | ||
| FFO | SBP | 2 | –0.19 (–0.26 to –0.13) | <0.001 | I2=9%, P for Cochran Q= 0.29 | 4 | 0.83 (0.78 to 0.88) | <0.001 | I2=0%, P for Cochran Q=0.43 |
| DBP | 2 | –0.01 (–0.07 to 0.05) | 0.780 | I2=8%, P for Cochran Q=0.30 | 1 | 0.97 (0.84 to 1.12) | 0.680 | - | |
| FI | SBP | 4 | –0.19 (–0.23 to –0.15) | <0.001 | I2=0%, P for Cochran Q=0.64 | 4 | 0.70 (0.57 to 0.87) | 0.001 | I2=79%, P for Cochran Q<0.01 |
| DBP | 3 | 0.00 (–0.04 to 0.04) | 1.000 | I2=0%, P for Cochran Q=0.70 | 1 | 0.86 (0.68 to 1.09) | 0.210 | - | |
| sICH | SBP | 3 | 0.50 (0.14 to 0.86) | 0.006 | I2=33%, P for Cochran Q=0.23 | 4 | 1.13 (1.01 to 1.25) | 0.030 | I2=63%, P for Cochran Q=0.04 |
| DBP | 3 | 0.20 (–0.31 to 0.71) | 0.450 | I2=57%, P for Cochran Q=0.10 | 2 | 1.07 (0.92 to 1.26) | 0.380 | I2=36%, P for Cochran Q=0.21 | |
| Mortality | SBP | - | - | - | - | 3 | 1.17 (0.99 to 1.40) | 0.070 | I2=47%, P for Cochran Q=0.15 |
| DBP | - | - | - | - | 1 | 1.09 (0.81 to 1.47) | 0.570 | - | |
BP, blood pressure; SMD, standardized mean difference; CI, confidence interval; OR, odds ratio; FFO, favorable functional outcome (modified Rankin Scale [mRS] 0–1); SBP, systolic blood pressure; DBP, diastolic blood pressure; FI, functional independence (mRS 0–2); sICH, symptomatic intracranial hemorrhage.
*
In the adjusted for potential confounders analyses all associations of SBP/DBP with the outcomes of interest are presented per 10 mm Hg SBP/DBP increment.